
Caribou Biosciences Investor Relations Material
Latest events

Q1 2025
8 May, 2025

Q4 2024
10 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Caribou Biosciences Inc
Access all reports
Caribou Biosciences Inc. is a clinical-stage biopharmaceutical company at the forefront of genome editing technology. It focuses on developing genome-edited allogeneic cell therapies for the treatment of cancer and other devastating diseases. The company utilizes CRISPR-Cas9 technology to create precise, directed changes in the DNA of living cells, aiming to develop innovative therapies that can address unmet medical needs. Caribou's leading product candidates include allogeneic chimeric antigen receptor T (CAR-T) cell therapies for hematologic malignancies and solid tumors. This approach allows for the development of therapies that are not patient-specific but can be used as "off-the-shelf" treatments, potentially reducing time and cost compared to traditional autologous CAR-T therapies. The company is headquartered in Berkeley, CA, and its shares are listed on the NASDAQ.
Key slides for Caribou Biosciences Inc


Corporate Presentation
Caribou Biosciences Inc


Corporate Presentation
Caribou Biosciences Inc
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
CRBU
Country
🇺🇸 United States